Advanced Accounting 12th Edition by Joe Ben Hoyle,Thomas Schaefer , Timothy Doupnik

Exercise 48

On March 7, 2012, Celgene Corporation acquired all of the outstanding stock of Avila Therapeutics, Inc. in exchange for $352.2 million in cash plus contingent consideration. Referring to Celgene's 2012 financial statements answer the following questions regarding the Avila Therapeutics acquisition.
How did Celgene account for the contingent consideration portion of the deal What is the maximum potential contingent consideration payout to the former owners of Avila Therapeutics